|
|
|
| Correlation between the levels of serum anti-mullerian hormone and Betatrophin of patients with low ovarian reserve and their ovarian reactivity and pregnancy outcomes after in vitro fertilization-embryo transfer |
| Guangxi Zhuang Autonomous Region Maternal and Child Health Care Hospital, Nanning, Guangxi Zhuang Autonomous Region, 530003 |
|
|
|
|
Abstract To explore the correlation between the levels of serum anti-mullerian hormone (AMH) and Betatrophin of patients with low ovarian reserve (LOR) and their ovarian reactivity and pregnancy outcomes after in vitro fertilization-embryo transfer (IVF-ET). Methods: The clinical data of 137 patients with LOR who had undergone IVF-ET from December 2019 to December 2022 were collected in this study. These patients were divided into group A (112 patients with LOR), group B (16 patients with normal ovarian reactivity) and group C (9 patients with high ovarian reactivity) according to their ovarian reactivity. These patients also were divided into group D (44 patients with success pregnancy) and group E (93 patients with pregnancy failure) according to their pregnancy situation. Enzyme-linked immunosorbent assay was used to detect the serum AMH and Betatrophin levels of these patients. Receiver operator characteristic (ROC) curve was used to evaluate the predictive value of the serum AMH and Betatrophin levels of the patients with LOR for their pregnancy outcomes after IVF-ET. The influencing factors of the pregnancy outcomes of the patients with LOR after IVF-ET were explored by multivariate logistic regression. Results: The serum AMH level of the patients in group A (0.49±0.13 ng/ml), in group B (0.98±0.21 ng/ml) and in group C (1.05±0.26 ng/ml) had increased gradually. The serum Betatrophin level of the patients in group A (156.95±16.33 pg/ml), in group B (112.17±13.42 pg/ml) and in group C (92.64±11.03 pg/ml) had decreased gradually. The level of serum AMH level (1.07±0.36 ng/ml) of the patients in group D was significantly higher than that (0.34±0.19 ng/ml) of the patients in group E, and the level of Betatrophin (136.29±14.42 pg/ml) of the patients in group D was significantly lower than that (216.16±21.05 pg/ml) of the patients in group E (all P<0.05). The area under the curve (AUC) of the levels of serum AMH level, the Betatrophin level and the combined levels of serum AMH and Betatrophin of the patients with LOD for predicting their pregnancy outcomes after IVF-ET was 0.857, 0.771 and 0.904, respectively. Multivariate logistic regression analysis showed that the follicle-stimulating hormone/ luteinizing hormone ratio ≥2, the poor ovarian response, the AMH level ≤0.71ng/ml, and the Betatrophin level ≥176.23pg/ml of the patients with LOD were the independent risk factors of their pregnancy failure after IVF-ET (P<0.05). Conclusion: The serum AMH and Betatrophin levels of the patients with LOD are associated with their ovarian reactivity and pregnancy outcomes after IVF-ET, and both of which can be used as the potential biomarkers to predict the pregnancy outcomes of the patients after IVF-ET.
|
|
|
|
|
|
|
|
|
